Generic Name |
certolizumab |
---|---|
Strength |
200 mg/mL |
Form | subcutaneous injection solution |
Special Authority Criteria |
Approval Period |
---|---|
For the treatment of ankylosing spondylitis according to established criteria described in the Special Authority forms 5365 (Initial/Switch) and 5366 (Renewal), below. Coverage of certolizumab for the treatment of ankylosing spondylitis is available only when certolizumab is prescribed by a rheumatologist |
1 year |
Click on the appropriate Special Authority Form below for full criteria.